Brian Rifkin
@brianrifkin.bsky.social
General and Interventional Nephrologist #MedSky #NephSky, pragmatist, lover of memes/GIFs/bad dad jokes, artist, singer, NephJC editor, NephSIM mentor, GlomCon grad. Air Force veteran and type 1 diabetic (insulin pimp).
Reposted by Brian Rifkin
That was quick!
The US FDA approves Sibeprenlimab aka Voyxact for reducing proteinuria in IgA
www.fda.gov/drugs/novel-...
#NephSky
#TopNephrology
The US FDA approves Sibeprenlimab aka Voyxact for reducing proteinuria in IgA
www.fda.gov/drugs/novel-...
#NephSky
#TopNephrology
November 26, 2025 at 12:21 AM
That was quick!
The US FDA approves Sibeprenlimab aka Voyxact for reducing proteinuria in IgA
www.fda.gov/drugs/novel-...
#NephSky
#TopNephrology
The US FDA approves Sibeprenlimab aka Voyxact for reducing proteinuria in IgA
www.fda.gov/drugs/novel-...
#NephSky
#TopNephrology
Reposted by Brian Rifkin
November 25, 2025 at 6:42 PM
Reposted by Brian Rifkin
An announcement
www.nephjc.com/news/2025/11...
#NephJC
@kidneyboy.bsky.social and moi hand over the @nephjc.bsky.social reigns to @nephroseeker.medsky.social & @brianrifkin.bsky.social
www.nephjc.com/news/2025/11...
#NephJC
@kidneyboy.bsky.social and moi hand over the @nephjc.bsky.social reigns to @nephroseeker.medsky.social & @brianrifkin.bsky.social
Taking the reigns — NephJC
In April 2014, Swapnil and I launched NephJC—and within weeks we were overwhelmed by the sheer work of running a twice-monthly, Twitter-based journal club. Fortunately, we also had a deep bench of fri...
www.nephjc.com
November 25, 2025 at 12:03 PM
An announcement
www.nephjc.com/news/2025/11...
#NephJC
@kidneyboy.bsky.social and moi hand over the @nephjc.bsky.social reigns to @nephroseeker.medsky.social & @brianrifkin.bsky.social
www.nephjc.com/news/2025/11...
#NephJC
@kidneyboy.bsky.social and moi hand over the @nephjc.bsky.social reigns to @nephroseeker.medsky.social & @brianrifkin.bsky.social
Reposted by Brian Rifkin
#NephJCshort on BICAR-ICU2 #Medsky #Nephsky
✍️ By @nephroseeker.medsky.social
🎭 Bicarbonate makes the picture look cleaner: better pH, more time. But beneath the smoother numbers, the patient hasn't changed. It's the same story, just told in softer colors
www.nephjc.com/news/2025/10...
✍️ By @nephroseeker.medsky.social
🎭 Bicarbonate makes the picture look cleaner: better pH, more time. But beneath the smoother numbers, the patient hasn't changed. It's the same story, just told in softer colors
www.nephjc.com/news/2025/10...
Dialysis deferred, logic recycled: BICAR ICU2 — NephJC
NephJC short on BICAR-ICU2
www.nephjc.com
November 25, 2025 at 12:19 AM
#NephJCshort on BICAR-ICU2 #Medsky #Nephsky
✍️ By @nephroseeker.medsky.social
🎭 Bicarbonate makes the picture look cleaner: better pH, more time. But beneath the smoother numbers, the patient hasn't changed. It's the same story, just told in softer colors
www.nephjc.com/news/2025/10...
✍️ By @nephroseeker.medsky.social
🎭 Bicarbonate makes the picture look cleaner: better pH, more time. But beneath the smoother numbers, the patient hasn't changed. It's the same story, just told in softer colors
www.nephjc.com/news/2025/10...
Reposted by Brian Rifkin
Getting to Know Dr. Rashid Sharaf ✨
He shares why ASDIN meetings matter and how the next generation is shaping the field.
🩺 Interventional Nephrology Day — Dec 17
🎉 Then: #ASDIN2026
Full interview here: youtu.be/HGiHoCq0OXg?...
He shares why ASDIN meetings matter and how the next generation is shaping the field.
🩺 Interventional Nephrology Day — Dec 17
🎉 Then: #ASDIN2026
Full interview here: youtu.be/HGiHoCq0OXg?...
November 22, 2025 at 1:20 AM
Getting to Know Dr. Rashid Sharaf ✨
He shares why ASDIN meetings matter and how the next generation is shaping the field.
🩺 Interventional Nephrology Day — Dec 17
🎉 Then: #ASDIN2026
Full interview here: youtu.be/HGiHoCq0OXg?...
He shares why ASDIN meetings matter and how the next generation is shaping the field.
🩺 Interventional Nephrology Day — Dec 17
🎉 Then: #ASDIN2026
Full interview here: youtu.be/HGiHoCq0OXg?...
Calling all Fellows & Physicians in Training!
ASDIN’s Annual Scientific Meeting includes a special Fellows Education Course just for you!
Click here to see the full schedule! 💻✨
cdn.ymaws.com/www.asdin.or...
ASDIN’s Annual Scientific Meeting includes a special Fellows Education Course just for you!
Click here to see the full schedule! 💻✨
cdn.ymaws.com/www.asdin.or...
November 24, 2025 at 9:13 PM
Reposted by Brian Rifkin
How can the nephrology community accelerate the adoption of life-saving treatments? Some drugs initially designed to treat diabetes have shown promise in preserving kidney function. Read more about ASN's new paradigm: saving kidneys, hearts, and lives. #ASNKidneyNews kidney.pub/KN1710-15
November 24, 2025 at 4:00 PM
How can the nephrology community accelerate the adoption of life-saving treatments? Some drugs initially designed to treat diabetes have shown promise in preserving kidney function. Read more about ASN's new paradigm: saving kidneys, hearts, and lives. #ASNKidneyNews kidney.pub/KN1710-15
Some more useful videos from @ASDINNews and the National Association of Nephrology Technicians
(NANT)
m.youtube.com/playlist?lis...
(NANT)
m.youtube.com/playlist?lis...
NANT-ASDIN Webinars 2025 - YouTube
m.youtube.com
November 22, 2025 at 1:58 PM
Some more useful videos from @ASDINNews and the National Association of Nephrology Technicians
(NANT)
m.youtube.com/playlist?lis...
(NANT)
m.youtube.com/playlist?lis...
Reposted by Brian Rifkin
In patients with cardiovascular disease and low or low-normal potassium levels, whether increasing levels to the high-normal range lowers the risk for ventricular arrhythmias is unclear. Research findings from the POTCAST trial are summarized in a new Quick Take video. nej.md/49JTckP
November 21, 2025 at 2:23 PM
In patients with cardiovascular disease and low or low-normal potassium levels, whether increasing levels to the high-normal range lowers the risk for ventricular arrhythmias is unclear. Research findings from the POTCAST trial are summarized in a new Quick Take video. nej.md/49JTckP
Reposted by Brian Rifkin
Reposted by Brian Rifkin
Looking for great Christmas gifts?!
Everyone looks adorable and feels cozy in #HCWvsHunger swag
www.bonfire.com/hcwvshunger-...
Everyone looks adorable and feels cozy in #HCWvsHunger swag
www.bonfire.com/hcwvshunger-...
November 21, 2025 at 3:13 AM
Looking for great Christmas gifts?!
Everyone looks adorable and feels cozy in #HCWvsHunger swag
www.bonfire.com/hcwvshunger-...
Everyone looks adorable and feels cozy in #HCWvsHunger swag
www.bonfire.com/hcwvshunger-...
#NephSky
Sure SNAP is back, but people are still going hungry.
Be thankful, grateful, and humble and give to a worthy cause…a local food bank #HCWvsHunger
Sure SNAP is back, but people are still going hungry.
Be thankful, grateful, and humble and give to a worthy cause…a local food bank #HCWvsHunger
Planning to participate in #HCWvsHunger this year?
Let me know and I can be sure you’re on one of my starter packs!
Let me know and I can be sure you’re on one of my starter packs!
November 21, 2025 at 1:19 AM
#NephSky
Sure SNAP is back, but people are still going hungry.
Be thankful, grateful, and humble and give to a worthy cause…a local food bank #HCWvsHunger
Sure SNAP is back, but people are still going hungry.
Be thankful, grateful, and humble and give to a worthy cause…a local food bank #HCWvsHunger
Reposted by Brian Rifkin
Planning to participate in #HCWvsHunger this year?
Let me know and I can be sure you’re on one of my starter packs!
Let me know and I can be sure you’re on one of my starter packs!
November 21, 2025 at 1:13 AM
Planning to participate in #HCWvsHunger this year?
Let me know and I can be sure you’re on one of my starter packs!
Let me know and I can be sure you’re on one of my starter packs!
Reposted by Brian Rifkin
Every year, #NephJC celebrates successful, practice-changing trials. ✨ Which trials do you think are deserving for #TopNephrology 2025? #nephsky
👇👇 Here's a throwback for 2024
www.nephjc.com/news/2024/1/...
👇👇 Here's a throwback for 2024
www.nephjc.com/news/2024/1/...
Top Stories in Nephrology 2024 — NephJC
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every b...
www.nephjc.com
November 20, 2025 at 10:42 PM
Every year, #NephJC celebrates successful, practice-changing trials. ✨ Which trials do you think are deserving for #TopNephrology 2025? #nephsky
👇👇 Here's a throwback for 2024
www.nephjc.com/news/2024/1/...
👇👇 Here's a throwback for 2024
www.nephjc.com/news/2024/1/...
Reposted by Brian Rifkin
Explore the evolving role of surrogate endpoints and how eGFR trends and proteinuria can guide prognosis and treatment decisions in real world clinical practice.
🎧
🎧
Kidney Commute
Tune in for the latest research and perspectives on kidney health from NKF.
bit.ly
November 21, 2025 at 1:00 AM
Explore the evolving role of surrogate endpoints and how eGFR trends and proteinuria can guide prognosis and treatment decisions in real world clinical practice.
🎧
🎧
Reposted by Brian Rifkin
🧵 New #Skeetorial Drop! 🧵
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
November 20, 2025 at 6:47 PM
🧵 New #Skeetorial Drop! 🧵
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
Reposted by Brian Rifkin
1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
November 20, 2025 at 12:34 AM
1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Reposted by Brian Rifkin
T3g: #NephJC
Although sibeprenlimab targets APRIL alone while atacicept blocks both BAFF and APRIL, the two trials showed broadly similar clinical effects: meaningful reductions in proteinuria, strong improvements in key biomarkers, and high rates of hematuria resolution.
Although sibeprenlimab targets APRIL alone while atacicept blocks both BAFF and APRIL, the two trials showed broadly similar clinical effects: meaningful reductions in proteinuria, strong improvements in key biomarkers, and high rates of hematuria resolution.
November 19, 2025 at 2:42 AM
T3g: #NephJC
Although sibeprenlimab targets APRIL alone while atacicept blocks both BAFF and APRIL, the two trials showed broadly similar clinical effects: meaningful reductions in proteinuria, strong improvements in key biomarkers, and high rates of hematuria resolution.
Although sibeprenlimab targets APRIL alone while atacicept blocks both BAFF and APRIL, the two trials showed broadly similar clinical effects: meaningful reductions in proteinuria, strong improvements in key biomarkers, and high rates of hematuria resolution.
Reposted by Brian Rifkin
as learned in the #nephjc IgAN g/l's chat, it should be IgA IgB IgC etc.. but uses Greek alphabet- thread: bsky.app/profile/kidn...
Joel Topf, just out of the shower where I was wondering why it is:
IgG
IgM
IgA
IgE
Rather than
IgA
IgB
IgC
IgD
IgE
#NephJC
IgG
IgM
IgA
IgE
Rather than
IgA
IgB
IgC
IgD
IgE
#NephJC
November 19, 2025 at 2:40 AM
as learned in the #nephjc IgAN g/l's chat, it should be IgA IgB IgC etc.. but uses Greek alphabet- thread: bsky.app/profile/kidn...
Reposted by Brian Rifkin
⏰ 90 min until #NephJC chat
Inertia is a strong force, mostly since for decades we only had RASi and steroids (we'll leave fish oil for another day 😉)
Just look at the only graded recommendations in 2021 @kdigo.org
pubmed.ncbi.nlm.nih....
Inertia is a strong force, mostly since for decades we only had RASi and steroids (we'll leave fish oil for another day 😉)
Just look at the only graded recommendations in 2021 @kdigo.org
pubmed.ncbi.nlm.nih....
November 19, 2025 at 12:30 AM
⏰ 90 min until #NephJC chat
Inertia is a strong force, mostly since for decades we only had RASi and steroids (we'll leave fish oil for another day 😉)
Just look at the only graded recommendations in 2021 @kdigo.org
pubmed.ncbi.nlm.nih....
Inertia is a strong force, mostly since for decades we only had RASi and steroids (we'll leave fish oil for another day 😉)
Just look at the only graded recommendations in 2021 @kdigo.org
pubmed.ncbi.nlm.nih....
Reposted by Brian Rifkin
⏰ One hour to go #NephJC
Two decades on, the nephro-universe is unrecognizable. IgAN't just about slowing CKD anymore; it's paradigm shifting.
🎙️Listen to @freelyfiltered.bsky.social episode
Two decades on, the nephro-universe is unrecognizable. IgAN't just about slowing CKD anymore; it's paradigm shifting.
🎙️Listen to @freelyfiltered.bsky.social episode
Episode 72: Nefecon for IgAN, The NefIgArd part B trial — NephJC
Nefecon, coated budesonide, is the first drug labelled for IgA nephropathy
and the approval path, 9-month reduction in proteinuria followed by 2 year
GFR data set the stage for the GN renaissance we are currently living
through.
www.nephjc.com
November 19, 2025 at 1:00 AM
⏰ One hour to go #NephJC
Two decades on, the nephro-universe is unrecognizable. IgAN't just about slowing CKD anymore; it's paradigm shifting.
🎙️Listen to @freelyfiltered.bsky.social episode
Two decades on, the nephro-universe is unrecognizable. IgAN't just about slowing CKD anymore; it's paradigm shifting.
🎙️Listen to @freelyfiltered.bsky.social episode
Reposted by Brian Rifkin
Check out the awesome visual abstract by @salinesolut.bsky.social
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
ORIGIN-3: The Visual Abstract — NephJC
Atacicept, BAFF/APRIL inhibition in IgAN
www.nephjc.com
November 18, 2025 at 12:32 PM
Check out the awesome visual abstract by @salinesolut.bsky.social
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
Reposted by Brian Rifkin
Resuman Visual
Revisa el resumen visual realizado por Clemens Weber @salinesolut.bsky.social . Gracias @dramiliflores.bsky.social !
www.nephjc.com/news/2025/11/17/origin-3-el-resumen-visual
Revisa el resumen visual realizado por Clemens Weber @salinesolut.bsky.social . Gracias @dramiliflores.bsky.social !
www.nephjc.com/news/2025/11/17/origin-3-el-resumen-visual
ORIGIN-3: El Resumen Visual — NephJC
ORIGIN-3 ha llegado a NephJC con atacicept en NIgA. Un paso sólido hacia una terapia dirigida anti BAFF/APRIL, que aborda la fisiopatología desde su origen. ¡Las señales tempranas son prometedoras! R...
www.nephjc.com
November 18, 2025 at 12:38 PM
Resuman Visual
Revisa el resumen visual realizado por Clemens Weber @salinesolut.bsky.social . Gracias @dramiliflores.bsky.social !
www.nephjc.com/news/2025/11/17/origin-3-el-resumen-visual
Revisa el resumen visual realizado por Clemens Weber @salinesolut.bsky.social . Gracias @dramiliflores.bsky.social !
www.nephjc.com/news/2025/11/17/origin-3-el-resumen-visual
Reposted by Brian Rifkin
Tonite 11/18/25 on #Bluesky 9pm EST
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
Attacking the Origin of IgAN: ORIGIN3 and Atacicept — NephJC
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
www.nephjc.com
November 18, 2025 at 12:29 PM
Tonite 11/18/25 on #Bluesky 9pm EST
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
